PJA1 (Praja1, encoded by the PJA1 gene) is a RING finger E3 ubiquitin ligase that plays a critical role in protein quality control and ubiquitination. Originally identified in mouse brain, Praja1 has emerged as an important regulator of neurodegeneration through its ability to ubiquitinate and degrade pathological proteins including [tau](/proteins/tau), [TDP-43](/mechanisms/tdp-43-proteinopathy), SOD1, FUS, [α-synuclein](/proteins/alpha-synuclein), and [huntingtin](/proteins/huntingtin).[@watabe2025]
Gene Information
Gene Structure
The PJA1 gene encodes a RING-type E3 ubiquitin ligase characterized by:
RING finger domain: Zinc-binding motif conferring E3 ligase activity
Coiled-coil region: Protein-protein interactions
Transmembrane domain: Subcellular localization
Function
Normal Cellular Function
Praja1 is primarily localized to the endoplasmic reticulum (ER) and performs several key functions:
Protein quality control: Targeted degradation of misfolded proteins
ER-associated degradation (ERAD): Part of the [unfolded protein response](/entities/unfolded-protein-response)
Signal transduction: Modulation of various cellular signaling pathways
Development: Essential for embryonic development in mice
Ubiquitination Targets
Praja1 has been shown to ubiquitinate:[@watabe2025]
Role in Neurodegeneration
Tau Degradation
Aoki et al. demonstrated that Praja1 ubiquitinates and degrades hyperphosphorylated tau, a key molecule in tauopathies including:[@watabe2025]
Alzheimer's disease
Pick's disease
Progressive supranuclear palsy (PSP)
Corticobasal degeneration (CBD)
This finding positions Praja1 as a potential therapeutic target for enhancing tau clearance in CBS and related disorders.
Several single nucleotide polymorphisms (SNPs) have been identified in the PJA1 gene, though their functional significance in neurodegeneration remains under investigation.
Disease Associations
While PJA1 mutations are not a major cause of familial neurodegeneration, reduced Praja1 activity may contribute to:
Sporadic Alzheimer's disease
Idiopathic Parkinson's disease
Age-related cognitive decline
Therapeutic Implications
Enhancing Praja1 Activity
Given Praja1's broad substrate specificity for disease proteins, strategies to enhance its activity could provide therapeutic benefits:
Small molecule activators: Compounds that increase Praja1 expression or activity
[Watabe K et al., Praja1 E3 ubiquitin ligase and the role it plays in neurodegeneration. FEBS J (2025) (2025)](https://pubmed.ncbi.nlm.nih.gov/41466523/)
[Aoki et al., Praja1 ubiquitinates and degrades tau (n.d.)](https://pubmed.ncbi.nlm.nih.gov/31779667/)